Abstract
BACKGROUND: Helicobacter pylori infection is a prevalent global health issue, especially in developing countries. Due to increasing antibiotic resistance, sequential therapy regimens have been proposed as alternatives to standard treatment. This study aimed to evaluate the efficacy and safety of a 1-week sequential regimen containing furazolidone and metronidazole compared to the standard triple therapy for H. pylori eradication. METHODS: In this randomized, parallel-group clinical trial, 110 patients with confirmed H. pylori infection were randomly assigned to either the intervention group (sequential therapy) or the control group (standard regimen). The primary outcome was H. pylori eradication assessed by stool antigen test 4 weeks after treatment. Secondary outcomes included adverse effects. Data were analyzed using chi-square and other appropriate statistical tests. RESULTS: The eradication rate was significantly higher in the intervention group than in the control group (76.4% vs. 56.4%, χ² = 4.928, P = 0.043). Adverse events were less frequent in the intervention group, including nausea (16.4% vs. 23.6%, P = 0.03), altered taste (10.9% vs. 18.2%, P = 0.002), loss of appetite (7.3% vs. 14.5%, P = 0.006), and dizziness (5.5% vs. 0%, P = 0.048). CONCLUSION: The 1-week sequential regimen demonstrated significantly higher eradication rates and better tolerability compared to the standard triple therapy. This approach may offer a more effective and safer option for treating H. pylori infection.